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Whose job is it to implement personalized medi cine? This is a key question for healthcare in the early 21st Century. Advances in informatics and molecular technologies, disease understand ing, pharmacogenetics, systems biology and translational medicine, along with the reduced costs of biomarker and genetic/genomic testing, have taken us to the threshold of a new way to practice medicine that has the potential to optimize individualized treatment and improve patient outcomes. Swen et al. recently reviewed the neces sary steps, progress and hurdles along the path leading to the integration of personal ized medicine into clinical practice but did not dwell on the initial requirement for the creation and testing of viable individualized treatment hypotheses [1] . In addition, most reviews deal ing with the clinical translation of pharmaco genomic testing have primarily dealt with varia tion in drug exposure and resultant efficacy and safety issues, although the potential clinical and drugdevelop ment applications of other types of pharmacogenomic data are mentioned [1, 2] . Outside of oncology there is little evidence for the efficient translation of diseasespecific pharmacogenomic data into the clinic. In fact, there is a growing gap between our knowledge of genetic and biomarkerrelated individual differences that relate to diseaserele vant bio logical processes, disease predisposition and expression, and the application of this knowl edge in clinical practice. Who will create, test and clinically validate diseaserelated person alized medicine hypo theses as a first step towards closing this gap? Who will support these activities? What strategies and incentives will governments, regulatory agencies, profes sional organizations, academic institutions and third party payers adopt to help translate these types of personalized medicine clinical para digms into standard practice? These questions are addressed in this article and are illustrated using personalized medicine hypotheses for rheumatoid arthritis (RA).
Translational medicine clinical scientists are well equipped to create and test diseasespecific personalized medicine hypotheses as a first step towards validating individualized treat ment para digms. The strategies used to develop person alized medicine paradigms are the same as those addressed by translational medicine groups in the pharmaceutical industry when developing drugs with novel targets and mechanisms, but the starting points are reversed. Translational medi cine scientists in the pharmaceutical industry begin with novel drug targets and mechanisms Advances in the molecular definition of disease, biomarker technologies and informatics have brought us to the threshold of a new way to individualize treatment for patients -personalized medicine. However, while the clinical translation of drug metabolism and cancer-related genomics data has resulted in accepted individualized treatment paradigms, this has not occurred as frequently or efficiently for patients with common chronic diseases such as rheumatoid arthritis. This gap between the rapidly increasing amount of disease-related genomic information and its clinical translation can be addressed through the creation and testing of personalized medicine treatment hypotheses using the same strategies that translational medicine scientists utilize to achieve proof-of-concept for drugs with novel targets. This is illustrated with three testable personalized medicine hypotheses for rheumatoid arthritis where known genetic markers in patients can potentially be used to select the most appropriate treatments and dose. Incentives resulting from changes in government and regulatory agency policies, investments in sample and data repositories, acceptance of new economic models by pharmaceutical companies and third party payers as well as more training, research support and academic opportunities for translational medicine scientists are all needed to speed up the implementation of personalized medicine for patients with rheumatoid arthritis and other common chronic diseases.
future science group PeRsPective Littman PeRsPective Littman based on the molecular understanding of abnormal pathway expression in disease, they test molecules that modulate those targets and have specific absorption, distribution, metabo lism and excretion (ADME) characteristics that determine the drug's pharmacokinetic profile and then use biomarkers to select 'molecularly correct' human populations that optimize effi cacy and safety signals in early proofofconcept (POC) studies [3] . As illustrated in Figure 1 , when developing personalized medicine paradigms, the strategy is the same but the order of the steps is reversed. Clinical translational medicine sci entists begin with patient characteristics (dis ease subpopulations/biomarkers and pharmaco genetics) and select the best drug mechanism, drug molecule and dose based on these.
Translational medicine strategies for creating and testing diseaserelated personalized medi cine hypotheses are built around some basic concepts. Disease definition has traditionally relied on clinical and pathological descriptions, for example, nonsmallcell lung cancer, a dis ease phenotype. Traditional disease definitions are now being replaced by molecular disease definitions. Again, cancer is a good example where oncogene mutations (e.g., K-RAS [4] ), gene overexpression (e.g., HER-2 [5] ) and spe cific bio markers (e.g., estrogen receptor positiv ity [6] ) are all used to describe the disease and have treatment implications. Thus, a disease phenotype may be further defined molecularly into subpopulations based on various types of biomarkers. This is just as relevant to common chronic diseases as it is to cancer.
Drugs are developed based on knowledge of specific molecular targets thought to be impor tant in disease expression. Figure 2 illustrates two other concepts that are important for personal ized medicine paradigms when considering selec tion of the best drug target for an individual [7] . The first, illustrated by the black solid curve, is that the level of abnormal activity expression (lower or higher) of a biochemical pathway that is responsible for any specific aspect of a disease phenotype is related to the severity of that aspect of the disease. A drug targeting that abnormality will be most effective in patients with the most abnormal expression of that pathway. The second is that patients with the same disease phenotype do not all have the same level of abnormal activ ity of a biochemical pathway or expression of a drug target; there is a distribution of patients with differing degrees of abnormal pathway expression and the distribution is specific to each disease relevant pathway. Therefore, the shape of this distribution determines the percentage of patients with that disease who will have a signifi cant ther apeutic response to a drug whose target modu lates the expression of the pathway. In Figure 2 , the population with the highest (upper 25%) abnormal pathway expression was arbitrarily selected to illustrate this, since this population would be expected to have a much greater than average response to a drug targeting this path way. A very efficacious personalized medicine treatment paradigm could be a prerequisite for rapid acceptance and could also be more easily confirmed in small clinical trials where large dif ferences between a subpopulation's response and the response of an unselected disease population are needed. With this level of abnormal pathway expression, the proportion of patients who are very responsive to a drug targeting this pathway is highly dependent on the distribution of path way expression in the overall disease population. The three hypothetical distributions illustrated here result in anywhere from a very small popula tion of patients (approximately 5%) who are very good responders to almost half of the patients being good clinical responders.
Oncology is leading the way with multiple examples of the clinical translation of molecular disease knowledge into personalized medicine treatment strategies that are becoming the stan dard of care. This makes sense given the trend towards the molecular rather than the patho logical definition of cancers, clinically validated biomarkers and diagnostics that help in this process and guide therapeutic decisions and specific targeted biologics and small molecules.
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Translational strategies to implement personalized medicine PeRsPective For example, K-RAS wildtype is required for good clinical responses to antiEGF receptor (EGFR) antibodies in colon cancer [4] , HER2 over expression is required for good clinical responses to trastuzumab in breast cancer [5] , estrogen receptor expression in breast cancer predicts responsiveness to selective estrogen antagonists such as tamoxifen [6] and EGFR mutations determine the sensitivity or resis tance to EGFR tyrosine kinase inhibitors in lung cancer, since these mutations can modulate expression of the actual drug target (binding site) [8, 9] . Here, the relationship between onco gene and biomarker expression, the neoplastic phenotype and response to targeted agents has been demonstrated in clinical trials and has become part of the standard of care for cancer patients. Likewise, individual differences that influence drug exposure are very important in cancer patients receiving traditional chemo therapeutic agents with a narrow therapeutic index. Clear differences in efficacy and safety can become apparent when the same dose of these drugs is used in different patients with out considering their individual drug metabo lism capabilities. In a classic study, Petros et al. demonstrated important differences in survival between genetically defined sub populations of breast cancer patients receiving the same treat ment protocol [10] . In this study, retrospective Kaplan-Meier analyses of overall longterm survival in breast cancer patients following standarddose chemotherapy and highdose cyclophosphamide, cisplatin and carmustine were performed for patients segregated based on the presence of genetic polymorphisms in CYP3A4*1B, CYP3A5*1, MET1F G-7T and glutathioneStransferase M1. Survival differ ences between the optimal genetically defined sub populations and unselected populations at 8 years after re staging ranged from 15-30%. Other examples of the acceptance of pharmaco genetic testing to guide dosing are rare outside of oncology unless, like cancer chemo therapeutic agents, the drug has a narrow therapeutic index. One example where such testing is also becom ing standard of care is warfarin [11] . Clinical translation of pharmaco genetic differences influencing drug exposure in these situations is an important consideration for personal ized medicine and has been largely accepted by physicians and regulatory agencies, espe cially when the safety or efficacy of the drug is clearly improved. However, the clinical trans lation of diseaserelated genetic differences into personalized medicine treatment paradigms deserves more focus and can be approached using the translational medicine strategies described above. The dark solid black curve illustrates the clinical response to a drug that targets the pathway and the response increases with the degree of abnormal expression of that pathway. The dashed line represents the distribution of pathway expression for a specific target pathway in patients with a disease. The shaded area represents patients that will have the best response to a drug targeting that pathway. Data from [7] .
future science group
Oncologists rapidly adopt individualized treatment paradigms owing to the urgency felt when treating patients with a lifethreatening disease. As a result, these personalized medicine regimens for cancer patients are becoming the standard of care in almost real time, from the initial scientific observations to the creation, test ing and confirmation of personalized medicine hypotheses. On the other hand, there is a large body of knowledge that could be used to create similar personalized medicine hypotheses for patients with common chronic diseases and as yet, this is not happening on a large scale and it is certainly not happening quickly. This gap between the knowledge of individual genetic differences associated with disease patho genesis, progression and severity and the translation of that knowledge into testable personalized medi cine hypo theses can be addressed by translational medicine scientists.
The best way to illustrate how translational medicine scientists can efficiently translate dis easerelated genomic data and other types of bio marker information into personalized medicine treatment paradigms is with specific examples. RA is one such chronic disease that is ripe for the creation and testing of personalized medicine hypotheses. RA is a heterogeneous phenotype, associated with multiple molecular differences and inflammatory pathway abnormities that dif fer between patients. Here, the development of effective targeted biological and small molecule drugs [12] , advances in the understanding of the molecular biology of immunologic and inflam matory pathways including the role of cyto kines in RA [13] and the functional significance of SNPs in relevant genes can lead to testable individualized treatment hypotheses. At least 19 specific genes are significantly associated with RA susceptibility, severity or response to ther apy and have been associated with differences in Tlymphocyte activation, macrophage func tion, specific cytokine and inflammatory sig naling pathways and/or inflammatory pathway dysregulation [101] . While these same pathways are targeted by biological drugs, rheumatologists treat their patients without considering these individual differences and instead they use a 'try it and see' paradigm. These agents were approved because they are safe and effective for the 'aver age patient'. In other words, in each study, the mean efficacy for the drug group was statistically better than that of the control group. Yet for biol ogics targeting TNF, approximately 29-54% of patients do not achieve clinically important efficacy (American College of Rheumatology Criteria 20 [ACR20] response [Box 1]) [12] and the per patient cost of a 6month treatment trial is in the range of US$5000-US$7000 [14] . In addition, for the nonresponders, more effective treatment is delayed by 6 months. Similarly, for tocilizumab, an antiIL6 receptor antibody, 30-40% of patients do not achieve an ACR20 response [15] [16] [17] . With abatacept, a CTLA4Ig construct, only 60% of patients achieve an ACR20 response when administered with methotrexate compared with 30% on metho trexate alone [18] . For each of these treatments, testable personalized medicine hypotheses can be evaluated in either new prospective clinical trials or retrospectively by using stored samples from completed doseranging clinical studies.
Dose selection for TNF-a-targeted agents
TNFa production is influenced by SNPs in the promoter region of the gene and is associated with outcomes in malaria and other infectious diseases. For example, the 308 G→A SNP has a gene frequency of 0.23 (in a Swedish study) [19] and probably has clinical significance since it is associated with a number of infectious, allergic and autoimmune diseases [102] . It has functional significance since in vitro cells from subjects with A/A and A/G genotypes produce significantly more TNFa in response to inflammatory stimuli and there are clear differences in trans cription rates [20, 21] . In RA, this SNP may have clinical significance as well. In a RA study with infliximab, clinically significant improvement occurred in 81% of G/G patients compared with 42% of A/A and A/G patients [22] . This sug gests that a standard infliximab treatment regi men during disease flares may not be sufficient to neutralize increased levels of TNFa. This hypothesis can be tested and, if confirmed, may lead to a more rational approach to dose selec tion in RA patients. Currently, G/G patients (approximately 60% of the population) may be receiving more antiTNFa than they need while A/G and A/A patients may require higher doses or more frequent treatment to prevent disease flares. Individualized dosing from the beginning of therapy could reduce infectious adverse events and improve efficacy.
Patient & dose selection for tocilizumab
Tocilizumab is an antiIL6 receptor antibody that is approved for RA treatment in Europe [103] and is expected to be approved in the near future in the USA. A third of patients treated with
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Translational strategies to implement personalized medicine PeRsPective tocilizumab in Phase II and Phase III clini cal trials did not achieve an ACR20 clinical response [15] [16] [17] . A common SNP at position 174 of the IL-6 gene changes the amount of IL6 produced upon stimulation with IL1 and other inflammatory stimuli [23, 24] . The C allele fre quency is relatively high -0.403 in the general population of London, UK -but is signifi cantly reduced in patients with juvenile RA [23] . C/C constructs do not increase IL6 production after stimulation with IL1 or lipo polysaccharide compared with the 2.35 and 3.6fold increase by G/C and G/G constructs, respectively [23] .
Could the nonresponders to tocilizumab be patients whose disease is less dependent on IL6 (i.e., C/C genotype) or patients who produce more IL6 (i.e., G/C and G/G genotypes)? Again, these are testable hypotheses with the potential to improve patient outcomes by identify ing those patients who are most likely to respond or those patients requiring a higher dose of tocilizumab.
Patient selection for abatacept
Abatacept is a fusion molecule of CTLA4 and an Fc fragment of IgG. It blocks interaction between CD28 and CD80/86 (B7-1 and B7-2), mimicking the natural CTLA4mediated down regulation of Tlymphocyte immune responses by inhibiting the costimulation pathway [25] . Approximately 40% of patients who receive abatacept on methotrexate background therapy do not achieve an ACR20 response [18] . PTPN22 is a lymphoidspecific phosphatase that down regulates Tlymphocyte activation mediated by CD28 costimulation and ligation of the Tcell receptor [26] . A SNP (1858 C→T) in the PTPN22 gene results in an amino acid change from arginine to tryptophan at position 620 and reduces phosphatase function [27] . This SNP is present in 17% of the general population and in 28% of RA patients [27] . It is reason able to assume that abatacept may be more active in patients with a PTPN22 SNP that results in decreased phos phatase function and a more active costimulation pathway. Abatacept directly targets this costimu lation pathway. It is currently prescribed in RA patients who have first failed a diseasemodifying antirheumatic drug (DMARD), but it may make sense to use abatacept first in patients with this 1858 C→T SNP if it can be demonstrated that this sub population of patients has a much higher response rate than the general RA population. Again, this is a testable hypothesis with the poten tial to improve patient outcomes and reduce the cost of medical care.
What can be done to move these types of hypotheses forward into medically acceptable and reimbursable individualized treatment paradigms more rapidly? First, investments in infrastructure such as electronic medical records (EMRs) linked to sample repositories and sup port of training programs in translational medi cine will facilitate the creation and testing of hypotheses concerning individualized treatment paradigms and the clinical validation of associ ated biomarkers. These investments by academic centers, hospitals, clinics and third party payers could also become a source of revenue for these institutions since others could pay for access to test their own hypotheses or share in the intel lectual property discoveries (biomarkers, diag nostics, drug targets and treatment indications) that have commercial value. These types of investments have also been identified by others as being critical to the future implementation of personalized medicine treatment paradigms [1, 2] . For pharmaceutical companies, these invest ments could also reduce the cost and time of drug development as well as increase research productivity [28, 104] . In addition, using their own data and samples, pharmaceutical and biotech companies could retrospectively evaluate person alized medicine hypotheses during the course of drug development at little additional cost, prefer entially in early development but even after Phase II and III trials are complete, to potentially reduce latephase attrition.
If translational medicine clinical scientists are successful and more personalized medicine hypotheses are created, tested and clinically valid ated, what else is needed to implement these treatment paradigms in medical practice? First, there must be some demonstration of more favorable outcomes (cost-benefit) over conven tional treatment paradigms and pharmaceutical companies should be allowed to alter pricing to reflect this improved cost-benefit. Second, if the opinion expressed here, analyses by the Boston Consulting Group [104] and the views of other academic and industry experts [2, 28] , are cor rect, the cost and time to develop drugs linked to pharmacogenomic tests and/or diagnostics 
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future science group PeRsPective Littman PeRsPective Littman will be reduced compared with drugs that have 'blockbuster' marketing targets, and pharma ceutical companies will consider personalized medicine paradigms for new drugs, especially with the active involvement of regulatory authorities. However, it is unlikely that phar maceutical companies will adopt label changes for successfully marketed drugs without finan cial incentives or new regulatory requirements. In some of the RA examples presented above, the difference in revenue between the current 'try it for 6 months' paradigm and a personal ized medicine paradigm where potential non responders never receive an expensive biological drug is approximately US$250,000 for every new 100,000 RA patients. For drugs in develop ment, it is also unlikely that Phase III programs will be tailored towards personalized medicine paradigms rather than more inclusive labeling claims unless marketing approval is at stake or other financial incentives exist. For example, Roche (Basel, Switzerland) has not published any data on the efficacy of tocilizumab in RA subpopulations identified by the IL6 promoter SNPs discussed above, despite the availability of the samples and the data to test this person alized medicine hypothesis [Littman BH, Translational Medicine Associates, CT, USA & Woodworth T, Roche Products Ltd and Hoffmann-La Roche, Basel, Switzerland. Pers. Commun.]. Their Phase II and III studies included patients who failed to respond to other DMARDs so it is likely that this is the indication they are seeking in the USA [15] [16] [17] . It is also the approved indication in Europe [103] . Again, the demonstration of superior clini cal outcomes and cost-benefit advantages are required if these treatment paradigms are to be adopted by clinicians, payers and regulators.
Given these considerations, after the success ful validation of personalized medicine hypo theses, clinical implementation of the treatment paradigm requires not only the demonstra tion of improved clinical outcomes but also a cost-benefit advantage in disease populations. In RA, such studies have been conducted to jus tify the high cost of biological DMARDs (often supported by pharmaceutical and biotechnology companies) but they have not been conducted to test the cost-effectiveness of specific personal ized medicine treatment paradigms. In a review of eight studies [29] , the authors found that the cost of a quality adjusted life year (QALY) for RA patients who are resistant to methotrexate and receiving biological therapy ranged from US$3580 to US$119,578 with 13 of 22 differ ent treatment comparisons in those eight studies showing the incremental cost of a QALY for biologics to be over US$50,000. Since some of this high cost includes the cost of treating nonresponders, it would be considerably lower for these same drugs if personalized medicine treatment paradigms were adopted, where the probability of a significant clinical response with acceptable safety would be much higher and where patients who are less likely to respond will not be treated. Future studies in RA will also have to better quantitate the 'opportunity cost' of ineffective or less effective treatments that allow joint damage to progress until a more effective treatment is received.
The responsibility for creating, testing and implementing personalized medicine treatment hypotheses should belong to academic medical institutions, hospitals, pharmaceutical compan ies, government agencies, physicians and third party medical payers who all have a significant stake in the success, cost-effectiveness and clinical validity of a widely accepted personalized medicine future scenario. As noted above, infrastructure invest ments in universal EMR systems and repositories for clinical data and samples for research purposes will facilitate hypothesis gener ation and testing, but universal EMRs will also enable quality of care and cost-effectiveness comparisons to be made between conventional and personalized treatment regimens. In fact, the ability of uni versal EMRs to facilitate quality of care and drug effectiveness comparisons is one of the reasons why the Obama administration has made univer sal EMRs in the USA such a high priority for both economic recovery and improved healthcare [30] . They will also help to better define phenotypes for subjects in clinical trials and reduce the cost of pharmacogenomics in general [28, 31] . Clinical and outcomes research studies that evaluate spe cific personalized medicine treatment paradigms should be conducted and/or funded by those insti tutions that will benefit by using the data to make decisions that improve the cost-effectiveness of healthcare delivery; third party payers (govern ment and private) have the greatest financial incentives while academic institutions, regulatory agencies, physicians and patients have the greatest clinical incentives to further evaluate and imple ment clinically validated personalized medicine treatment paradigms.
Hypothetical models, such as the one pro posed by Garrison and Finley [32] , can be used to predict the general economic impact of person alized medicine, but it is unlikely that they will provide the necessary motivation and incentives that will result in the acceptance of specific A u t h o r P r o o f future science group Translational strategies to implement personalized medicine PeRsPective person alized treatment paradigms. Adopting these one at a time once their benefit is demon strated in studies grounded in the reality of a comparison of outcomes data is the more likely future scenario. Personalized medicine clini cal grants from government agencies and third party payers as well as new outcomes research regulatory requirements during the develop ment of drugs with testable personalized medi cine hypotheses will also provide an incentive to conduct this type of research. Finally, academic medical institutions and professional organiza tions should reward translational medicine and personalized medicine outcomes research suc cesses, much as they do the more traditional laboratorybased research successes.
Training and education in translational medicine is the last piece of the puzzle that is needed to help implement personalized medi cine. In the pharmaceutical company environ ment, trans lational medicine clinical scientists have generally been trained internally and have backgrounds in early clinical research, clinical pharmacology, pharmacogenomics and biol ogy. There is a great need for new translational medicine training programs and this could be facilitated by collabo rations between industry, government and academic institutions [33] . The US FDA and the NIH have recognized the need to advance this area with their 'Critical Path' [105, 106] and 'Clinical and Translational Science Awards' [107] initiatives, but again, progress has been slow outside of oncology. Some universi ties have recently set up translational medicine departments or spinoff institutions to address this need [34] . Currently, many educational pro grams focused on pharmacogenomics are found in pharmacology departments and pharmacy schools with more of a focus on how genetic fac tors influence drug exposure [35] . More investment is needed in educational programs that focus on the clinical translation of new knowledge regard ing the molecular definition of chronic diseases, molecularly defined disease subpopulations and responsive ness to drugs targeting their specific molecular and pathway abnormalities.
In summary, the concepts presented here for translating the molecular definition of disease phenotypes, particularly of functionally impor tant genetic associations, into testable personal ized medicine hypotheses is within the expertise of translational medicine scientists and apply to all chronic diseases. This process has much in common with the way translational medicine experts in the pharmaceutical industry approach the demonstration of POC for drugs with novel targets. However, the real world is quite different from the pharmaceutical company environment. There is no question regarding who is respons ible for demonstrating the activity of novel drugs within a company while the responsibility for cre ating and testing personalized medicine hypo theses in the real world remains to be defined. Clearly, new academic opportunities, educational programs and rewards for translational medicine researchers, financial and regulatory incentives for drug companies and developers, EMR and sample repository infrastructure investments and the demonstration of improved clinical outcomes and cost-benefit advantages are all required to make personalized medicine a reality.
Future perspective
Personalized medicine has the potential to sat isfy the need to reduce drugdevelopment costs and time, reduce healthcare costs and improve health outcomes. This will be the driver towards implementing personalized medicine treatment paradigms for patients with common chronic diseases over the next 5-10 years. As we are see ing with the clinical translation of molecular disease knowledge in cancer into personalized medicine treatment practices, this will occur one by one for patients with common chronic diseases. We will begin to see such examples and the demonstration of their cost-effective ness over the next 5 years. The clinical and regulatory acceptance of these examples along with their reimbursement by payers will pro vide motivation for pharmaceutical companies, regulators, third party payers and translational medicine scientists to further advance personal ized medicine and develop new drugs specifi cally targeting molecularlydefined patient sub populations. Academic institutions, third party payers (including governments), hospitals and clinics will help to develop the infrastructure to facilitate personalized medicine research and its acceptance into clinical practice, but it will be the payers who will eventually insist on its implementation based on cost-effectiveness.E 
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